Company News

Share this article:
Novartis announced an agreement with Vanda Pharmaceuticals for exclusive US and Canandian rights for Fanapt, a schizophrenia treatment approved by FDA in May. The agreement included an upfront payment of $200 million, and potential milestones and sales royalties in the future. Vanda retained rights to the drug outside of the US and Canada, although Novartis has the option to discuss further collaboration as new opportunities arise.

Onyx Pharmaceuticals will acquire Proteolix, Inc., a privately-held biopharmaceutical company focused on discovering and developing therapies for hematological malignancies and solid tumors. Onyx will pay $276 million for the company, and other milestone payments pending regulatory approvals. Proteolix's lead compound is currently in clinical trials, including a phase 2b trial for relapsed and refractory multiple myeloma.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters